An Open Randomized Study of Comparative Pharmacokinetics and Biosimilarity of GP40221, Solution for Subcutaneous Administration 1.34 mg/ml (GEROPHARM) and Ozempic®, Solution for Subcutaneous Administration 1.34 mg/ml in Healthy Volunteers
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Romiplostim (Primary) ; Semaglutide (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors GEROPHARM
- 18 Jul 2024 New trial record